BRPI0716498A2 - Genes e polipeptídeos relacionados a cânceres de mama - Google Patents

Genes e polipeptídeos relacionados a cânceres de mama

Info

Publication number
BRPI0716498A2
BRPI0716498A2 BRPI0716498-0A2A BRPI0716498A BRPI0716498A2 BR PI0716498 A2 BRPI0716498 A2 BR PI0716498A2 BR PI0716498 A BRPI0716498 A BR PI0716498A BR PI0716498 A2 BRPI0716498 A2 BR PI0716498A2
Authority
BR
Brazil
Prior art keywords
polypeptides
breast cancer
related genes
genes
breast
Prior art date
Application number
BRPI0716498-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0716498A2 publication Critical patent/BRPI0716498A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
BRPI0716498-0A2A 2006-08-10 2007-08-10 Genes e polipeptídeos relacionados a cânceres de mama BRPI0716498A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83742806P 2006-08-10 2006-08-10
US84025006P 2006-08-25 2006-08-25
US91502207P 2007-04-30 2007-04-30
PCT/JP2007/065992 WO2008018642A2 (en) 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers

Publications (1)

Publication Number Publication Date
BRPI0716498A2 true BRPI0716498A2 (pt) 2015-01-27

Family

ID=38627000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716498-0A2A BRPI0716498A2 (pt) 2006-08-10 2007-08-10 Genes e polipeptídeos relacionados a cânceres de mama

Country Status (8)

Country Link
US (2) US8673548B2 (enExample)
EP (1) EP2057187B1 (enExample)
JP (1) JP5339291B2 (enExample)
KR (1) KR20090064378A (enExample)
BR (1) BRPI0716498A2 (enExample)
CA (1) CA2660438A1 (enExample)
SG (1) SG174071A1 (enExample)
WO (1) WO2008018642A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
KR20080052570A (ko) 2005-07-29 2008-06-11 타게티드 그로스 인코퍼레이티드 야생형 ｋｒｐ에 의한 활성 사이클린-ｃｄｋ 복합체 억제의우성 음성 돌연변이 ｋｒｐ 단백질 보호
JP5514453B2 (ja) * 2008-03-04 2014-06-04 株式会社キノファーマ 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
EP2275567A1 (en) * 2009-07-15 2011-01-19 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid expression construct and its use as a cell proliferation marker
CA2787673A1 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2012065166A2 (en) * 2010-11-12 2012-05-18 Targeted Growth, Inc. Dominant negative mutant kip-related proteins (krp) in zea mays and methods of their use
US9062323B2 (en) 2011-04-11 2015-06-23 The Regents Of The University Of California Identification and use of KRP mutants in wheat
WO2012142106A1 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and the use of krp mutants in plants
EP2738255B1 (en) * 2011-07-29 2016-11-23 Tokushima University Erap1-derived peptide and use thereof
CA3122778A1 (en) * 2011-10-28 2013-05-02 Oncotherapy Science, Inc. Topk peptides and vaccines including the same
ES2707232T3 (es) 2011-12-16 2019-04-03 Univ Nat Corp Tokyo Medical & Dental Acido nucleico bicatenario quimérico
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
US9903871B2 (en) 2014-07-15 2018-02-27 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from nucleoredoxin X1 and uses thereof
CN104497147B (zh) * 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
US10669310B2 (en) 2016-01-19 2020-06-02 Tokushima University Peptide for cancer treatment and pharmaceutical composition containing same
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
JP7291327B2 (ja) 2017-07-19 2023-06-15 国立大学法人徳島大学 ペプチド誘導体及びそれを含む医薬組成物
EP3889264A4 (en) 2018-11-30 2022-10-12 Tokushima University BREAST CANCER THERAPEUTIC WITH BIG3-PHB2 INTERACTION INHIBITING PEPTIDE FROM PHB2
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用
CN120944846A (zh) * 2025-10-15 2025-11-14 北京索莱宝科技有限公司 人PP1α蛋白及其Thr320位点磷酸化蛋白的抗原肽及其抗体的制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050064402A1 (en) * 2000-10-03 2005-03-24 Goldsworthy Susan Mcdonald Tumor marker and methods of use
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
AU2002246502A1 (en) 2000-11-17 2002-08-06 Hyseq, Inc. Nucleic acids and polypeptides
US20070015148A1 (en) 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003043568A2 (en) 2001-11-15 2003-05-30 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
WO2003064599A2 (en) 2002-01-25 2003-08-07 Origene Technologies, Inc Cancer genes
US6833247B2 (en) * 2002-05-14 2004-12-21 Origene Technologies, Inc. Regulated prostate cancer genes
US20030235533A1 (en) 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003260965A1 (en) 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Method for diagnosing testicular seminomas
US6971476B2 (en) * 2003-09-05 2005-12-06 D B Industries, Inc. Safety harness
JP4579246B2 (ja) * 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
BRPI0818533B8 (pt) * 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AU2009310310A1 (en) * 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK inhibitors containing the same

Also Published As

Publication number Publication date
WO2008018642A3 (en) 2008-04-03
US20110135647A1 (en) 2011-06-09
EP2057187A2 (en) 2009-05-13
JP2010500003A (ja) 2010-01-07
SG174071A1 (en) 2011-09-29
WO2008018642A2 (en) 2008-02-14
KR20090064378A (ko) 2009-06-18
EP2444417A1 (en) 2012-04-25
JP5339291B2 (ja) 2013-11-13
US8673548B2 (en) 2014-03-18
EP2057187B1 (en) 2016-12-28
US20140228238A1 (en) 2014-08-14
US9187557B2 (en) 2015-11-17
CA2660438A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
PT2115472E (pt) Biomarcadores de cancro
EP2045283A4 (en) HIGH REFRACTIVE INDEX MATERIAL
IL197573A0 (en) Directional use
FI20065391L (fi) Anturointijärjestely
EP2073652A4 (en) CLOTHING
GB0813682D0 (en) Proximity sensor
GB0715653D0 (en) Garments
IL221062B (en) Stitched polypeptides
BRPI0720226A2 (pt) Genes marcadores selecionáveis
GB0713413D0 (en) Phased based sensing
EP2087165A4 (en) BIOFUNCTIONAL MATERIALS
GB0610741D0 (en) Material detection
PL2001815T3 (pl) Materiał typu cementu
GB0620620D0 (en) Pervasive sensing
GB2460582B (en) Proximity sensing
EP2094218A4 (en) SENSOR
EP2180205A4 (en) ENERGY ABSORPTION MATERIAL
GB0619243D0 (en) Activation sensing
GB0616290D0 (en) Material
FI7587U1 (fi) Vetovoimamittalaite
GB0603248D0 (en) Portable object sensing assembly
GB0616558D0 (en) Garment
GB2428342B (en) Proximity sensing
TWI349218B (en) Displacement sensing device
GB0610720D0 (en) Material detection

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.